At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 190 enrolled
Drug / intervention
PF-05082566 +2 moredrug
Likely dose
rituximab 375 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1 STUDY OF PF-05082566 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED CANCER, AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL)
In Brief
A Phase 1 clinical trial evaluating PF-05082566 and rituximab for Lymphoma, Non-Hodgkin and 6 related conditions. Completed, enrolled 190 participants across 42 sites in 5 countries.
Detailed Summary
A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell of Head and Neck, Malignant Melanoma
CountriesAustralia, France, Italy, Japan, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartJun 2011
Primary CompletionFeb 2019
TodayJul 2026
First PostedMar 2, 2011
Enrollment StartJun 21, 2011
Primary CompletionFeb 20, 2019
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 15.3 years ago
Interventions
PF-05082566drug
Intravenous, Dose escalation, once per month
rituximabdrug
Intravenous, 375 mg/m2, once per week for 4 weeks
PF-05082566drug
IV, Dose escalation, once per month